Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now small index

Glycemic Response clinical trials

1 of 5 indexed Glycemic Response trials are currently recruiting.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Glycemic Response: 5 US clinical trials tracked, 1 recruiting.

Glycemic Response is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. The most active sponsor is Scripps Translational Science Institute, running 1 of these trials.

Enrollment posture brief

Registry condition glycemic-response

OPEN 1 | RECR 20% | LATE 0 | EARLY 0 | RANK #3391 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Glycemic Response (this)20%
Open-enrollment share among volume-matched conditions near Glycemic Response

Glycemic Response lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Glycemic Response on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Glycemic Response is recruiting below its size-band peers.

    1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Glycemic Response research.

    Scripps Translational Science Institute accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Glycemic Response trials plan to enrol fewer than 100 people.

    Median target enrolment is 40 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.

  4. Glycemic Response research is mostly interventional.

    4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase Distribution

Phase data not available

Named interventions

Most-linked intervention names on Glycemic Response records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

High GI Low carb Other
1 trials
Low GI Low Carb Other
1 trials
Low GI Other
1 trials
high GI Other
1 trials
Low flavonoid beverage Other
1 trials
Low flavoniod low essence beverage Other
1 trials
Concord Grape Juice Other
1 trials
Orange juice Other
1 trials

US sites by state

Facility locations filed on Glycemic Response trials. A trial with sites in several states counts in each.

California 2 trials
Pennsylvania 1 trials
Indiana 1 trials
Illinois 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Glycemic Response page

5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Glycemic Response condition card totals 5 registered trials; most-linked intervention High GI Low carb; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.